微电生理(688351) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 104,099,813.81, representing a 16.77% increase compared to CNY 89,152,510.16 in the same period last year[4] - Net profit attributable to shareholders reached CNY 17,870,494.14, a significant increase of 328.63% from CNY 4,169,185.75 year-on-year[4] - Basic and diluted earnings per share were both CNY 0.0380, reflecting a 326.97% increase from CNY 0.0089 in the same quarter last year[4] - Operating profit for Q1 2025 was CNY 17,932,298.02, significantly up from CNY 6,181,921.57 in Q1 2024, marking a 189.5% increase[18] - Total comprehensive income for Q1 2025 was CNY 17,869,070.17, compared to CNY 4,169,185.75 in Q1 2024, an increase of 328.5%[19] Cash Flow - The net cash flow from operating activities surged to CNY 34,790,900.13, marking a 455.68% increase compared to CNY 6,260,970.00 in the previous year[4] - Cash inflow from operating activities in Q1 2025 was CNY 123,477,571.15, compared to CNY 96,586,955.28 in Q1 2024, reflecting a 28.0% increase[19] - The net cash flow from investment activities was $34,944,133.15, a decrease from $129,739,268.51, indicating a decline in investment returns[20] - Cash inflow from financing activities was $379,881.15, with cash outflow totaling $899,061.79, leading to a net cash flow of -$519,180.64, down from -$2,414,583.20[20] - The net increase in cash and cash equivalents was $69,647,538.18, compared to $133,483,193.37 in the previous period, showing a decrease of approximately 47.9%[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,917,878,666.43, a 1.28% increase from CNY 1,893,682,970.18 at the end of the previous year[5] - The total current liabilities rose to RMB 117,874,688.02, compared to RMB 108,269,002.11 in the previous period, indicating an increase of about 8%[16] - The total liabilities of the company were reported at RMB 155,577,442.98, slightly up from RMB 151,946,998.96, marking a growth of around 2%[16] - The company's equity increased to RMB 1,762,301,223.45, compared to RMB 1,741,735,971.22, reflecting a growth of approximately 1.2%[16] Research and Development - Research and development expenses totaled CNY 20,692,617.34, a decrease of 10.80% from CNY 23,197,241.84, with R&D expenses accounting for 19.88% of operating revenue[5] - Research and development expenses decreased to CNY 13,417,634.91 in Q1 2025 from CNY 19,762,555.02 in Q1 2024, a reduction of 32.1%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,764, with the top ten shareholders holding a combined 73.23% of the shares[11] - The company has not reported any significant changes in shareholder relationships or actions among the top shareholders during the reporting period[13] Other Financial Metrics - The company reported non-recurring gains of CNY 5,310,185.97, primarily due to government subsidies and asset disposals[7] - The weighted average return on equity increased to 1.02%, up by 0.77 percentage points from 0.25%[4] - The company reported a foreign exchange loss of CNY 1,423.97 in Q1 2025[18] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[21]